Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Belite Bio, IncNASDAQ: BLTE
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $28.41K (cash outflow) rose 199.3% year over year, ahead of the +140.6% change in trailing-twelve-month net income. Sequentially, it rose 5.5% from the prior quarter. Over 3 fiscal years it compounded at +83.1% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$114.47M (+47.5%) for the fiscal year ending Dec 2026, a slowdown from the +114.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$28.41K+5.5% QoQ
- Last fiscal yearDec 2025
- -$77.61M+114.7% YoY
- LTMJun 2026
- -$102.36K+140.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +199.3% | +150362.4% | +150163.1 pp |
| 1 year | +114.7% | +47.5% | -67.2 pp |
| 3-year CAGR | +83.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (77.61M) USD
- Year-over-year change
- -114.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.61M) | -114.7% |
| FY2024 | 2024-12-31 | (36.14M) | -14.3% |
| FY2023 | 2023-12-31 | (31.63M) | -150.1% |
| FY2022 | 2022-12-31 | (12.65M) | -30.9% |
| FY2021 | 2021-12-31 | (9.67M) | — |
Net Income vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Jun 2026 net income of $102.36K is the smallest of the 6 companies compared; the peer median is $106.93M.
- Its year-over-year change of +140.6% is the highest of 5, against a peer median of +53.6%.
- Over three fiscal years its annual growth of +83.1% compares with a peer median of +11.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.6M | +85.0% | +31.4% | 3566.6% | |
| LTM Sep 2026 | $246.76M | +13.5% | -11.7% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $71.67M | +24.7% | -7.9% | 1605.2% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M | — | +41.0% | — |
BLTEBelite Bio, Inc | LTM Jun 2026 | $102.36K | +140.6% | +83.1% | — |
| Peer median (excluding BLTE) | $106.93M | +53.6% | +11.8% | 1605.2% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| Deferred Income Tax | 0 | (1.91M) | (4.69M) | 0 | 0 |
| Stock-Based Compensation | 1.53M | 1.48M | 3.82M | 8.99M | 38.92M |
| Change in Working Capital | 640K | (491K) | (2.43M) | 1.13M | 2.55M |
| Accounts Receivables | 0 | (32K) | (72K) | 74K | (66K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 640K | (459K) | (2.36M) | 1.06M | 2.62M |
| Other Non-Cash Items | (8K) | 1.91M | 4.69M | (3.66M) | (1.31M) |
| Operating Cash Flow | (7.47M) | (11.46M) | (29.84M) | (29.23M) | (36.99M) |
| Capital Expenditures | (74K) | (394K) | (63K) | (151K) | (178K) |
| Acquisitions (Net) | 18K | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (188.27M) | (451.99M) |
| Sales of Investments | 0 | 0 | 0 | 77.84M | 147.07M |
| Other Investing Activities | 0 | 0 | 0 | (35K) | 0 |
| Investing Cash Flow | (56K) | (394K) | (63K) | (110.57M) | (305.11M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | (583K) | 37.99M | 77.19M | 42.24M | 292.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.03M) | (1.23M) | 41.36M | 370.37M |
| Financing Cash Flow | (583K) | 36.96M | 75.96M | 83.6M | 663.23M |
| Effect of Forex Changes | (161K) | (366K) | 9K | (269K) | 117K |
| Net Change in Cash | (8.27M) | 24.75M | 46.07M | (56.48M) | 321.26M |
| Free Cash Flow | (7.55M) | (11.85M) | (29.9M) | (29.39M) | (37.17M) |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.